We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-5.00 | -0.29% | 1,700.00 | 1,699.50 | 1,700.50 | 1,711.00 | 1,695.50 | 1,705.00 | 758,662 | 10:24:33 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.24 | 70.2B |
Date | Subject | Author | Discuss |
---|---|---|---|
10/12/2018 15:56 | I have held some Glaxo shares since 1986. When I retired 20 years ago they were about £22, due I think to the imminent merger with SKB. Since then I have seen them fall to £10, but never above the £22 mark. I have pocketed many pounds from dividends during that time but always expected that one day they would climb back to over £22, when I would sell out. Some hope!!! More likely I will leave them to my children in my will, and maybe they will see the level I have hoped for! | jadeticl3 | |
10/12/2018 15:20 | £1 = $1.26 | tradermichael | |
10/12/2018 14:08 | hope so - I hold a lot of these indirectly so am always keen to see the price up but as I never sell it doesn't really matter. | nimbo1 | |
10/12/2018 14:01 | Its clear that GSK management sees a massive opportunity with a deal of this magnitude. It will take time to demonstrate it. Forget £17, £20+++ is possible in time | tradermichael | |
10/12/2018 13:58 | its galling though that if emma hadn't started playing roulette this share price would probably be at £17 now. Merry Christmas from GSK. | nimbo1 | |
10/12/2018 11:42 | Monty was running VOD down as the dividend was doomed, even at £1.45......best to ignore him? | trinderm | |
10/12/2018 08:31 | As the pound get weaker, more profit in real terms here. Divi safe, read the last few results / update. May have a problem breaking the £16 mark though. | blueteam | |
10/12/2018 08:22 | Always do the opposite to The Chronic Investor ….. ;0) | tradermichael | |
10/12/2018 08:03 | I'd be worried monty if you are starting to put any credence in TMF | ianood | |
10/12/2018 07:52 | Dividend it seems in danger then. | montyhedge | |
09/12/2018 21:06 | https://www.fool.co. | mj19 | |
07/12/2018 17:41 | McCall was EZJ CEO, Emmma is unproven in the role, unless it's the achievement of being GSK's first female CEO but if asked a survey question perhaps Emma is a default answer, high profile. | essentialinvestor | |
07/12/2018 17:31 | "ITV boss Carolyn McCall and GSK chief Emma Walmsley have been named Britain’s most admired leaders in a poll of top business executives." That's quite ridiculous; they've yet to prove themselves, but being a shareholder in both I hope that they come to be admired for the right reasons - making me wealthier :). | poikka | |
07/12/2018 17:21 | TM - Agree with your comments re overreaction. To ultimately become a growth stock again GSK needs to do precisely this type of deal, being conservative won't cut it in the long run. Don't really understand the rampant negativity, it's almost as if people just want a conservative company that pays a dividend and doesn't try to grow. | rikky72 | |
07/12/2018 17:06 | difficult to admire someone who makes a dogs dinner of a job | billionairepaddy | |
07/12/2018 16:48 | And look at the Share price of ITV since McCall took over! | fangorn2 | |
07/12/2018 16:29 | Admiration is not the same as successful. | semper vigilans | |
07/12/2018 16:22 | that choice must have been made a few days ago definitely not this week | billionairepaddy | |
07/12/2018 16:10 | How about this then: ITV boss Carolyn McCall and GSK chief Emma Walmsley have been named Britain’s most admired leaders in a poll of top business executives. The duo, two of the just six women who lead FTSE 100 companies, came out on top in a survey of 234 board directors, analysts and City commentators as part of Management Today’s Britain’s Most Admired Companies survey. | tradermichael | |
07/12/2018 15:55 | A deal of overreaction here, both from the market and this board …. ;0) | tradermichael | |
07/12/2018 15:31 | patience sorely tested with this poorly run over indebted company, if this elephant can claw its way back over 16 im out and will steer clear of pharma outside the US, the big US pharma companies seem to have a much better approach, something fundamentally wrong with gsk to be so pathetically range bound, I wonder if its one of those terminal ones that eventually just gets sold off or broken up, Whitbread a similar company, lacklustre management company going nowhere, took elliot to come in and blitz it. Imperial another. | porsche1945 | |
07/12/2018 10:13 | After reading all your posts the market has decided to retreat. | abdullla | |
07/12/2018 09:50 | MoneyWeek 'Has Glaxo paid too much for Tesaro?' | philanderer | |
07/12/2018 09:50 | ...There are reasons for the debt that I won't discuss here. Indeed there are. It's called poor management. | anhar |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions